2023
DOI: 10.1016/j.cpcardiol.2021.101035
|View full text |Cite
|
Sign up to set email alerts
|

Protease-Activated Receptor Antagonist for Reducing Cardiovascular Events – A Review on Vorapaxar

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(2 citation statements)
references
References 35 publications
0
2
0
Order By: Relevance
“…By inhibiting thrombin activity, the pathological process of atherosclerosis can be improved, and the risk of cardiovascular events can be reduced [14]. Thrombin is a serine protease that can hydrolyze various substrates, such as coagulation factors, fibrinolytic system factors, complement system factors, growth factors, and so on [15].…”
Section: Discovery and Characterization Of Panaxatriol As A Novel Thr...mentioning
confidence: 99%
“…By inhibiting thrombin activity, the pathological process of atherosclerosis can be improved, and the risk of cardiovascular events can be reduced [14]. Thrombin is a serine protease that can hydrolyze various substrates, such as coagulation factors, fibrinolytic system factors, complement system factors, growth factors, and so on [15].…”
Section: Discovery and Characterization Of Panaxatriol As A Novel Thr...mentioning
confidence: 99%
“…PAR-1 can be activated by thrombin to regulate platelet aggregation and endothelial permeability, so it is clinically used as a target for anti-platelet drugs to prevent thrombosis (125)(126)(127). Vorapaxar is a representative drug (128). IR induction was performed in rat lung models by perfusion in vitro.…”
Section: The Par-1 Antagonistmentioning
confidence: 99%